Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ACTRN12623000602628
ACTRN12623000602628RecruitingPhase 1

A Phase 1b, Open-label, Single-Arm Study Evaluating the Safety and Efficacy of GLX-100 in Adults with Interstitial Cystitis/Painful Bladder Syndrome.

Glycologix Australia PTY LTD0 sites40 target enrollmentStarted: June 1, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Sponsor
Enrollment
40
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomised trial
Primary Purpose
Treatment
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
Female

Inclusion Criteria

  • •1. Females aged 18 years or greater at the time of signing the informed consent form (ICF);
  • •2. Diagnosis of interstitial cystitis (IC)/ bladder pain syndrome (BPS) according to American Urological Association (AUA) Guidelines 2022 with symptoms for 6 months or more prior to screening;
  • •3. Visual analogue scale (VAS) bladder pain score of at least 4 (average pain during the last 3 days; scale 0 to 10) at Screening and Day 1 (prior to dosing);
  • •4. Had a prior cystoscopy to rule out confounding conditions;
  • •5. Been on unchanged acceptable oral medicines for IC/PBS for at least 3 months prior to Day 1;
  • •6. Positive bladder permeability test during the screening period;
  • •7. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to the first infusion and must not be breastfeeding, lactating or planning pregnancy during the study period. WOCBP must agree to use an acceptable form of contraception during the treatment period and for at least 8 weeks after the last instillation of the investigational medical device;
  • •WOCBP are defined as any female who has experienced menarche and who have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and are not postmenopausal.
  • •Menopause is defined as 12 months of amenorrhea in the absence of other biological causes.
  • •8. Be capable of giving informed consent and reading and signing the ICF after the nature of the study has been fully explained by the investigator or investigator designee;
  • •9. Be willing and able to complete all study assessments and procedures and to communicate effectively with the investigator and site staff.

Exclusion Criteria

  • •1. Known current Hunner’s lesions;
  • •2. McGill catastrophizing pain score >30;
  • •3. Received narcotics, oral immunosuppressives, pentosan polysulfate, tricyclic antidepressants (TCAs) (e.g., amitriptyline, pregabalin, or nortriptyline), or intravesical treatment for IC/PBS within 1 month, hydrodistension within 3 months, or intradetrusor Botulinum toxin (BOTOX) injections within 12 months prior Day 1;
  • •4. Has untreated endometriosis;
  • •5. Has recurrent urinary tract infection (UTI) (more than 3 UTIs over the last 12 months of the screening visit) or active UTI (positive bacterial urine culture) within 6 weeks prior to Day 1;
  • •6. Have a history of a clinically significant allergic reaction or hypersensitivity, as judged by the investigator, to any drug or any component of the study drug formulations used in the study (see Investigator’s Brochure);
  • •7. Active Coronavirus disease 2019 (COVID-19) infection within 2 weeks prior to Day 1;
  • •8. Active substance abuse (drugs or alcohol), history of chronic substance abuse within the past year, or prior chronic substance abuse judged by the investigator to recur during the study;

Investigators

Sponsor
Glycologix Australia PTY LTD

Similar Trials

Withdrawn
Phase 1
Evaluation of the Safety and Efficacy of CMB-012 in Subjects with Chemical Burns of theCornea and/or Persistent Corneal Epithelial Defects (PCED)Persistent Corneal Epithelial DefectChemical BurnEye - Diseases / disorders of the eyeInjuries and Accidents - Burns
ACTRN12619001724167Combangio, Inc.6
Active, not recruiting
Phase 1
A Clinical Trial to observe the effects of the test drug Rovalpituzumab Tesirine in patients with a particular form of Lung Cancer where no lasting efficacy has been achieved on at least two previous therapies.Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung CancerMedDRA version: 19.0Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10070308Term: Refractory cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004506-42-HUStemcentrx Inc.123
Active, not recruiting
Phase 1
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) - TRINITYRelapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10070308Term: Refractory cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004506-42-PLAbbVie Stemcentrx LLC342
Active, not recruiting
Phase 1
A Clinical Trial to observe the effects of the test drug Rovalpituzumab Tesirine in patients with a particular form of Lung Cancer where no lasting efficacy has been achieved on at least two previous therapies.Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10041070Term: Small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10070308Term: Refractory cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004506-42-DEAbbVie Stemcentrx LLC230
Active, not recruiting
Phase 1
A Clinical Trial to observe the effects of the test drug Rovalpituzumab Tesirine in patients with a particular form of Lung Cancer where no lasting efficacy has been achieved on at least two previous therapies.Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung CancerMedDRA version: 19.0 Level: PT Classification code 10041070 Term: Small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0 Level: PT Classification code 10070308 Term: Refractory cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004506-42-ESStemcentrx Inc.342